Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01706666 · ClinicalTrials.gov registry record · Phase 2
Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01706666: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01706666 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01706666, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well giving bortezomib with or without combination chemotherapy works as consolidation therapy in patients with newly diagnosed multiple myeloma who have completed stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, dexamethasone, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving bortezomib is more effective with or without combination chemotherapy in the post transplant setting.
Interventions
- OTHER laboratory biomarker analysis
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG lenalidomide
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-12-07 |
| Est. Completion | 2016-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01706666
The ClinicalTrials.gov registry entry for NCT01706666 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01706666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01706666 about?
NCT01706666 is a clinical study titled "Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant". This randomized phase II trial studies how well giving bortezomib with or without combination chemotherapy works as consolidation therapy in patients with newly diagnosed multiple myeloma who have completed stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the ...
What is the current status of trial NCT01706666?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2012-12-07. Estimated completion is 2016-05-17.
What interventions are being tested in trial NCT01706666?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cyclophosphamide (DRUG), dexamethasone (DRUG), lenalidomide (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT01706666?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.